GBI Appoints Industry Veteran Sven Lee to Board of Directors

Florida-based CDMO, GBI Biomanufacturing (GBI), has announced the appointment of Sven Lee to its board of directors. Mr. Lee brings decades of global experience in the biologics CDMO sector, having held executive and board positions at companies such as Abzena, Catalent, and Biocina, with expertise encompassing strategic growth, marketing, commercialization, licensing, and innovation in drug development.

GBI's Chairman and CEO, Karl Pinto, expressed enthusiasm about the addition, highlighting Mr. Lee's industry knowledge and reputation as assets that will enhance GBI's commitment to delivering high-quality development and manufacturing solutions to clients worldwide. Mr. Lee reciprocated, expressing his honor to join GBI during a period of significant investments and capacity expansion, aligning with his passion for advancing complex biopharmaceutical solutions.

GBI Biomanufacturing (GBI), a world-class, leading Contract Development and Manufacturing Organization (CDMO) based in Florida, is pleased to announce Sven Lee to its board of directors.

Sven brings to GBI decades of global experience in the biologics CDMO space, including multiple modalities and medical devices, having held C-suite and board positions at Abzena, Catalent, Biocina, among others. His expertise in specific skill areas such as strategic growth, marketing, commercialization, licensing and innovation in drug development will be instrumental in helping support and guide GBI as it continues to expand its capabilities and global reach.

“We are thrilled to welcome Sven to our board,” said Karl Pinto, Chairman & CEO of GBI. “He brings a wealth of industry knowledge, insights and a strong reputation that will strengthen our commitment to serve and deliver high-quality development and manufacturing solutions to our clients worldwide, something we have been doing for over thirty years as one of the world’s longest serving CDMOs”

“I am honored to join GBI Biomanufacturing’s Board of Directors at such an exciting time,” said Sven. “The company’s significant investments, dedication to service and technology excellence & reliability, new capacity expansion and ability to support biotech companies who are in the clinic right through to their BLA filings and commercialization align perfectly with my passion for advancing complex biopharmaceutical solutions. I look forward to contributing to GBI’s continued success and growth.”

With this strategic addition to its leadership team, GBI continues to strengthen its position as a trusted and reliable partner in the CDMO industry, providing innovative solutions and world-class manufacturing services to clients worldwide.

For more, please find the original story source here.